Biogen, Inc. (NQ: BIIB )

269.44 USD -0.68 (-0.25%)

Official Closing Price Updated: 7:56 PM EST, Jan 22, 2021 Add to My Watchlist

Price and Volume

Volume	691,100
Open	270.34
Bid (Size)	268.02 (1)
Ask (Size)	268.99 (1)
Prev. Close	270.12
Today's Range	268.48 - 272.70
52wk Range	223.25 - 374.99
Shares Outstanding	211,007,945
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Biogen Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

January 12, 2021

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of...

DEADLINE ALERT for TILE, BABA, and BIIB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

January 11, 2021

Performance

YTD	+10.90%	+10.90%
1 Month	+7.26%	+7.26%
3 Month	+1.68%	+1.68%
6 Month	-1.06%	-1.06%
1 Year	-5.20%	-5.20%

More News

Portnoy Law: Lawsuit Filed On Behalf of Biogen, Inc. Investors

January 11, 2021

Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone

January 11, 2021

LAWSUITS FILED AGAINST BIIB, SPLK and QSR - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS

January 10, 2021

March 5th Options Now Available For Biogen (BIIB)

January 21, 2021

Noteworthy Wednesday Option Activity: F, MS, BIIB

January 20, 2021

Why BioNTech's Multiple Sclerosis Vaccine Could Be a Game Changer

Today 6:04 EST

4 Stocks Warren Buffett Is Likeliest to Sell in 2021

January 22, 2021

Atalanta Therapeutics Launches With $110 Million to Pioneer RNAi Therapeutics for Neurodegenerative Diseases

January 11, 2021

10 Health Care Stocks Showing Unusual Options Activity In Today's Session

January 11, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.